Sequenom and LifeCodexx Partner to Commercialize Prenatal Laboratory Testing

Sequenom, Inc. (San Diego, CA, USA) has partnered with LifeCodexx AG (Konstanz, Germany) for the commercialization of prenatal laboratory testing services in Europe.

The companies have agreed to collaborate in the development and launch of a trisomy 21 laboratory developed test and other aneuploidies testing in Germany, Austria, Switzerland, and Liechtenstein, with the potential for additional launches in other countries.

LifeCodexx will make certain upfront and minimum annual royalty payments to Sequenom as well as royalties based on sales of testing services. Under this initial five year licensing agreement, Sequenom has granted LifeCodexx licenses to key patent rights that enable the development and commercialization of a noninvasive aneuploidy test utilizing circulating cell free fetal DNA in maternal plasma.

The completion of the agreement with LifeCodexx initiates Sequenom’s first European commercial partnership in the field of noninvasive prenatal diagnostics.

“We are pleased to be the first to partner with Sequenom and to initially provide this testing service to German speaking regions of the European market. We are now in a strong position to exploit the clinical utility and proprietary science behind the noninvasive detection of trisomy 21 and eventually other aneuploidies using shotgun sequencing as initially developed by Dr. Dennis Lo and his team,” commented Dr. Michael Lutz, CEO of LifeCodexx AG.

Related Links:
Sequenom, Inc.
LifeCodexx AG